

RECEIVED
CENTRAL FAX CENTER 004
MAR 05 2008Application Serial No. 10/533,158
Attorney Docket No. 7388/84325
Page 3Amendments to the Claims:

The following listing of claims replaces any prior listing of claims.

List of claims:

1. (Currently amended) An isolated nucleic acid comprising ~~one sequence selected from the group consisting of the nucleic acid sequences sequence~~ set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing.
2. (Cancelled)
3. (Currently amended) An isolated nucleic acid comprising the full complement complementary to the nucleic acid according to claim 1.
4. (Cancelled)
5. (Currently amended) An isolated nucleic acid probe comprising ~~nucleic acid (a) or nucleic acid (b):~~
(a) an isolated nucleic acid comprising a ~~partial length or the full length of one sequence selected from the group consisting of the nucleic acid sequences sequence~~ set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing, ~~or a nucleic acid complementary and the full complement of SEQ ID NO:1 thereto;~~
(b) a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing, or a nucleic acid complementary thereto.
6. (Cancelled)
7. (Cancelled)

Application Serial No. 10/533,158
Attorney Docket No. 7388/84325
Page 4

8. (Currently amended). A primer containing ~~DNA (a) or DNA (b)~~:

(a) ~~a-DNA an isolated nucleic acid comprising one sequence selected from the group consisting of the nucleic acid sequences sequence set forth in SEQ ID NO:175 to and SEQ ID NO:1076 NO:176 in the Sequence Listing, the full complement of SEQ ID NO:175, and the full complement of SEQ ID NO:176, or a DNA complementary thereto;~~

(b) ~~a DNA capable of hybridizing under stringent conditions to the DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:1076 in the Sequence Listing, or a DNA complementary thereto.~~

9. (Cancelled)

10. (Cancelled)

11. (Currently amended) A method for determining ~~whether a subject with neuroblastoma has stage 4s neuroblastoma, the method comprising detecting the presence or absence of [[a]] the nucleic acid comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing from a clinical tissue sample of neuroblastoma, wherein the presence of SEQ ID NO:1 indicates that the subject has stage 4s neuroblastoma.~~

12. (Currently amended) A nucleic acid microarray comprising a solid phase support and a combination of plural nucleic acids each comprising a partial length ~~or the full length nucleic acid comprising a an isolated nucleic acid comprising the nucleic acid sequence set forth in one of SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing immobilized on the solid phase support.~~

13. (Currently amended) A nucleic acid microarray comprising a solid phase support and ~~at least one isolated nucleic acid selected from the group consisting of a~~

*Application Serial No. 10/533,158
Attorney Docket No. 7388/84325
Page 5*

~~combination of plural nucleic acids each comprising a the nucleic acid sequence set forth in one of SEQ ID NO:175 to and the nucleic acid sequence set forth in SEQ ID NO:176 NO:200, a nucleic acid sequence set forth in one of SEQ ID NO:519 to SEQ ID NO:540 or a nucleic acid sequence set forth in one of SEQ ID NO:785 to SEQ ID NO:798, wherein the at least one isolated nucleic acid is immobilized on the solid phase support.~~

14. *(Cancelled)*

15. *(Cancelled)*

16. *(Cancelled)*

17. *(New)* A method for determining whether a subject with neuroblastoma has stage 4s neuroblastoma according to claim 11, wherein the presence of the nucleic acid sequence set forth in SEQ ID NO:1 is detected by a diagnostic agent comprising the isolated nucleic acid probe according to claim 5.

18. *(New)* A method for determining whether a subject with neuroblastoma has stage 4s neuroblastoma according to claim 11, wherein the presence of the nucleic acid sequence set forth in SEQ ID NO:1 is detected by a diagnostic kit comprising one pair of the primers according to claim 8.